secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOLIFE SOLUTIONS INC (BLFS)
CIK:        0000834365
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0001628280-25-001252
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioLife Solutions Q4 preliminary revenue $22.7M, +31% YoY; cell processing beats FY guidance
--------------------------------------------------------------------------------

- Q4 2024 continuing ops revenue $22.7M (+31% YoY); cell processing $20.3M (+37% YoY, +7% sequentially).
- FY2024 continuing ops revenue $82.3M (+8% YoY); cell processing $73.5M exceeded raised guidance of $72-73M.
- Evo and Thaw platform revenue fell 14% YoY to $8.7M for FY2024; Q4 down 8%.
- Company completed divestitures of freezer and biostorage businesses, sharpening focus on CGT market.
- CEO cites momentum, fortified balance sheet; full 2024 results and 2025 outlook due in February earnings call.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/834365/000162828025001252/0001628280-25-001252-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/834365/000162828025001252/blfs-20250113.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-001252

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer